A new generation of bias in EBM

For the latest Blogs go to www.cebm.net

 In the EUROPA trial  12,218 patients were randomized to receive perindopril or placebo. 9.9% of the participants in the ‘placebo’ group died or had a heart attack, whereas only 8% in the experimental group died or had a heart attack: roughly a 2% absolute effect size.  You would have to treat 50 patients with the drug to get one with a positive outcome.

According to current EBM standards, the EUROPA study provided very good evidence supporting the effects of perindopril because the study was large, randomized and double-blind. On this basis the authors of the study recommended that “all patients with coronary heart disease” should use the drug.

However, there are several problems with this and other large studies with small effects that are overlooked by standard EBM critical appraisal methods.

Exaggerating effect sizes

The authors of the EUROPA study reported the misleading relative effect size of 20% which…

View original post 564 more words


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s